A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients

Inclusion Criteria: * Male or female aged 18 to 60 years (inclusive); * Male weight ≥ 45 kg, female weight ≥ 40 kg, and body mass index (BMI, BMI = weight/height²): 18 kg/m² ≤ BMI ≤ 32 kg/m²; * HBsAg positive for more than 6 months (including 6 months), and with 100 IU/mL \< HBsAg \< 5000 IU/mL prior to randomization; * HBV DNA ≥ 100 IU/mL prior to randomization; * ALT ≤ 5 × ULN prior to randomization; * No prior interferon antiviral therapy within 1 year before the screening period, and no prior treatment with nucleos(t)ide analogues within 6 months before the screening period; * Males not having undergone sterilization surgery and females not postmenopausal for less than two years must agree to use adequate and effective contraceptive measures from screening until the last follow-up visit of the study (including hormonal contraceptives, intrauterine devices, cervical caps, or condoms); * Subjects must understand and comply with the study procedures, participate voluntarily, and sign the informed consent form. Exclusion Criteria: * Females who are pregnant, breastfeeding, or have a positive pregnancy test at baseline with childbearing potential. * Co-infection with hepatitis C, syphilis, or HIV. * History of alcoholic liver disease, non-alcoholic steatohepatitis, autoimmune liver disease or other hereditary liver diseases, drug-induced liver disease, or other clinically significant chronic liver diseases not caused by HBV. * History of or concurrent progressive liver fibr…